Dr. Steding remains committed to pursuing research in Breast Cancer with an emphasis on the molecular mechanisms that drive disease development, progression, metastasis, and chemoresistance. Paclitaxel, a microtubule-stabilizing compound, is of particular interest in studies of chemoresistance given its ongoing use clinically and the evidence of acquired chemoresistance in refractory disease. Cellular signaling pathways and their ability to confer or promote chemoresistance against paclitaxel remain poorly defined with a significant amount of conflicting information available. Preliminary whole-transcriptome analysis from paclitaxel-resistant cell lines performed in the Steding laboratory previously showed several pathways contribute to or are altered as a result of chemoresistance. Identifying which of the genes and pathways actually confer resistance represents the main focus of Dr. Steding's research.
Brooks, K., Holman, M., Steding, C., & Tucker, M. (2022). A founder CHEK2 pathogenic variant in association with kidney cancer. Cancer Genet, 262-263, 40-42.
Fry, D., Groepper, D., MacCarrick, G., Demo, E. M., Thomas, M. J., Wilkes, M. J., Lyons, M. J., Tucker, M. E., Steding, C. and Fleischer, J. (2022). Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype. Am J Med Genet A, 188(7), 2237-2241.
Brooks, K., Holman, M., Steding, C.E., and Tucker, M. (2020) A Founder CHEK2 Pathogenic Variant in Association with Kidney Cancer. National Comprehensive Cancer Network Virtual Annual Conference.
Brown, N., Cleghorn, K., Muse D., and Steding, C.E. (2019). Critically Evaluating In Vitro Conditions: Implications in Combating Cancer Derived from Long-Term Treatment with Commonly Used Compounds. Annual Biomedical Research Conference for Minority Students (ABRCMS). Anaheim, California. November 13-16, 2019.
Myers N, Mikolaj P, and Steding CE. (2018). Competing Policy Windows in Biotechnology: The FDA, the 21st Century Cures Act, and Laboratory Developed Tests. Review of Policy Research. 35, (1): 89-119.
Ghosh, S.K., Johnson, S.M., Steding, C.E., and Fitch, R. (2016). Adjuvanticity and Chemo-therapeutic Potential of Novel Phytol-derived Immunoadjuvants. International Congress of Immunology. August 21-26, 2016.
Steding, C. E. (2016). Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives. Future Oncol, 12(12), 1517-1527.
Sprouse, A. A., Steding, C. E., & Herbert, B. S. (2012). Pharmaceutical regulation of telomerase and its clinical potential. J Cell Mol Med, 16(1), 1-7.
Steding, C. E., Wu, S. T., Zhang, Y., Jeng, M. H., Elzey, B. D., & Kao, C. (2011). The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology, 133(2), 221-238.
Koziel, J. E., Fox, M. J., Steding, C. E., Sprouse, A. A., & Herbert, B. S. (2011). Medical genetics and epigenetics of telomerase. J Cell Mol Med, 15(3), 457-467.
Mellon, M. J., Bae, K. H., Steding, C. E., Jimenez, J. A., Kao, C., & Gardner, T. A. (2008). Suppression of renal cell carcinoma growth and metastasis with sustained antiangiogenic gene therapy. Hum Gene Ther, 19(5), 487-495.
© 2021 Marian University
Notice of Nondiscrimination
Marian University does not discriminate on the basis of race, ethnicity, color, sex, gender, gender identity, sexual orientation, religion, creed, national origin, age or disabilities in the selection of administrative personnel, faculty and staff, and students.
*Placement rates are gathered from data collected from graduates within six months of graduation.
Students may make a complaint to the Indiana Commission of Higher Education.
Marian University is sponsored by the Sisters of St. Francis, Oldenburg, Indiana.
Submit a Marketing Request
Website built with